First Phase II milestone reached for NovaBay's 3-in-1 antimicrobial auriclosene
This article was originally published in Scrip
Executive Summary
NovaBay Pharmaceuticals is attacking antibiotic resistance with three different formulations of a single novel product, auriclosene (NVC-422), and plans to move into Phase III development of an irrigation solution during the first half of 2014 based on positive Phase II results in the prevention of urinary catheter blockage and encrustation (UCBE).
You may also be interested in...
Finance Watch: Three New Life Science VC Funds Total Nearly $1bn
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Need a specific report? 1000+ reports available
Buy Reports